Government is working closely with the earliest import of Pfizer vaccine: VK Paul – government is working closely with the earliest import of pfizer vaccine, vk paul
Paul on Thursday said in a statement on ‘Myths and facts on India’s vaccination process’ that the supply of vaccines is limited globally. Companies have their own preferences, plans and constraints. Accordingly, they allot the vaccine. ”
Paul is also the head of the Kovid-19 workforce in India. “As soon as the availability of the vaccine was indicated by Pfizer, the central government and the company started working together to import it,” he said.
Paul, head of the National Expert Group (NEGVAC) on the administration of the vaccine for Kovid-19, said the efforts of the central government accelerated the trial of Sputnik’s vaccine and the timely approval of the two consignments of Russia vaccine and Indian with it Technology has been transferred to companies. Indian companies will soon start manufacturing vaccines.
A member of the NITI Aayog said that the center has been in constant dialogue with the world’s major vaccine companies such as Pfizer, JADJ and Moderna since mid-2020. The government has offered full support to these companies for the supply of vaccines and their manufacturing in India.
However, at the same time, Paul said that it is not the case that his vaccine is readily available for supply. “We need to understand that buying vaccines internationally is not the same as buying goods off a shelf.”
According to sources, Pfizer has told Indian officials that its vaccine is effective on the variety of SARS-COV-2 virus present in India. This vaccine can be applied to all people 12 years of age and older. It can be stored for a month at 2-8 degrees.
Pfizer has offered 50 million doses of the vaccine during July to October. However, it has sought some concessions and has held several discussions with Indian government officials. A meeting took place this week.
Paul denied allegations by some opposition leaders that the government was not doing enough to increase the domestic production of the vaccine.
He said that only one Indian company, Bharat Biotech, has IP. The government has ensured that three other companies / plants also start production of covaxine. Along with this, the capacity of Bharat Biotech plants has also been increased.
Paul said that Bharat Biotech’s production of covaxin will increase to 10 crore per month by October, which is currently less than 10 million per month.
#Government #working #closely #earliest #import #Pfizer #vaccine #Paul #government #working #closely #earliest #import #pfizer #vaccine #paul